NASDAQ:CCXI
Delisted
ChemoCentryx Stock News
$51.99
+0 (+0%)
At Close: Jan 27, 2023
ChemoCentryx: Q2 Earnings Insights
05:36pm, Monday, 09'th Aug 2021
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56), which missed the e
ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference
08:30am, Wednesday, 04'th Aug 2021
SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir
Analysts Estimate ChemoCentryx (CCXI) to Report a Decline in Earnings: What to Look Out for
04:46pm, Monday, 02'nd Aug 2021
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021
08:30am, Monday, 02'nd Aug 2021
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market clos
2 Beaten-Down Biotech Stocks That Could Bounce Back
06:13am, Tuesday, 27'th Jul 2021
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
ChemoCentryx: CRL Less Likely
11:04am, Sunday, 25'th Jul 2021
In my previous coverage, I said many analysts including myself thought a CRL was likely for avacopan. However, the FDA has accepted an amendment to the NDA and given an October 7 PDUFA date.
Is Now the Time to Buy ChemoCentryx Stock?
06:44am, Saturday, 10'th Jul 2021
Analysts following this risky biotech stock have changed their tune.
ChemoCentryx (CCXI) Files Amendment to NDA for Avacopan
10:32am, Wednesday, 07'th Jul 2021
ChemoCentryx (CCXI) files an amendment to its NDA for avacopan for treatment of ANCA-associated vasculitis. The new PDUFA date is Oct 7.
SAN DIEGO, July 7, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) against certain of its c
Why This ChemoCentryx Analyst Is Bullish
03:20pm, Tuesday, 06'th Jul 2021
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ:CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on
ChemoCentryx Stock Is Approaching A Key Level
01:55pm, Tuesday, 06'th Jul 2021
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmi
New York, New York--(Newsfile Corp. - July 6, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of ChemoCentryx, Inc.Shareholders w
New York, New York--(Newsfile Corp. - July 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
09:17am, Tuesday, 06'th Jul 2021
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil Cytoplasmic Autoantibod
Los Angeles, California--(Newsfile Corp. - July 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ChemoCentryx, Inc. ("